nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Intracranial pressure increased—Carmustine—melanoma	0.0245	0.0271	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.0127	0.014	CcSEcCtD
Doxylamine—Lacrimation—Docetaxel—melanoma	0.0112	0.0124	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.0107	0.0119	CcSEcCtD
Doxylamine—Redness—Docetaxel—melanoma	0.00976	0.0108	CcSEcCtD
Doxylamine—Liver disorder—Docetaxel—melanoma	0.00966	0.0107	CcSEcCtD
Doxylamine—Erythema multiforme—Vemurafenib—melanoma	0.0092	0.0102	CcSEcCtD
Doxylamine—Eye disorder—Vemurafenib—melanoma	0.0091	0.0101	CcSEcCtD
Doxylamine—Cardiac disorder—Vemurafenib—melanoma	0.00903	0.00998	CcSEcCtD
Doxylamine—Mediastinal disorder—Vemurafenib—melanoma	0.00877	0.00969	CcSEcCtD
Doxylamine—Erythema—Vemurafenib—melanoma	0.00847	0.00936	CcSEcCtD
Doxylamine—Rhinorrhoea—Docetaxel—melanoma	0.00813	0.00899	CcSEcCtD
Doxylamine—Diplopia—Carmustine—melanoma	0.00744	0.00822	CcSEcCtD
Doxylamine—Bone disorder—Docetaxel—melanoma	0.00729	0.00806	CcSEcCtD
Doxylamine—Bronchospasm—Bleomycin—melanoma	0.00725	0.00801	CcSEcCtD
Doxylamine—Diplopia—Temozolomide—melanoma	0.00719	0.00795	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.00716	0.00791	CcSEcCtD
Doxylamine—Lacrimation increased—Docetaxel—melanoma	0.00715	0.0079	CcSEcCtD
Doxylamine—Affect lability—Temozolomide—melanoma	0.00708	0.00782	CcSEcCtD
Doxylamine—Pancytopenia—Bleomycin—melanoma	0.007	0.00773	CcSEcCtD
Doxylamine—Anaphylactic shock—Vemurafenib—melanoma	0.00691	0.00764	CcSEcCtD
Doxylamine—Mood swings—Temozolomide—melanoma	0.00681	0.00753	CcSEcCtD
Doxylamine—Nervous system disorder—Vemurafenib—melanoma	0.00678	0.00749	CcSEcCtD
Doxylamine—Dehydration—Temozolomide—melanoma	0.00669	0.00739	CcSEcCtD
Doxylamine—Pancytopenia—Dactinomycin—melanoma	0.00652	0.00721	CcSEcCtD
Doxylamine—Breast disorder—Temozolomide—melanoma	0.0065	0.00718	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Temozolomide—melanoma	0.00647	0.00716	CcSEcCtD
Doxylamine—Hypotension—Vemurafenib—melanoma	0.00646	0.00714	CcSEcCtD
Doxylamine—Pancytopenia—Carmustine—melanoma	0.00611	0.00675	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00607	0.00671	CcSEcCtD
Doxylamine—Sweating increased—Temozolomide—melanoma	0.00605	0.00669	CcSEcCtD
Doxylamine—Decreased appetite—Vemurafenib—melanoma	0.00601	0.00664	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00597	0.0066	CcSEcCtD
Doxylamine—Fatigue—Vemurafenib—melanoma	0.00596	0.00659	CcSEcCtD
Doxylamine—Constipation—Vemurafenib—melanoma	0.00591	0.00653	CcSEcCtD
Doxylamine—Pancytopenia—Temozolomide—melanoma	0.0059	0.00652	CcSEcCtD
Doxylamine—Depression—Carmustine—melanoma	0.00572	0.00632	CcSEcCtD
Doxylamine—Agranulocytosis—Dactinomycin—melanoma	0.00572	0.00632	CcSEcCtD
Doxylamine—Depression—Temozolomide—melanoma	0.00552	0.00611	CcSEcCtD
Doxylamine—Hepatitis—Dactinomycin—melanoma	0.0055	0.00608	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00549	0.00607	CcSEcCtD
Doxylamine—Flushing—Bleomycin—melanoma	0.00547	0.00605	CcSEcCtD
Doxylamine—Erythema multiforme—Dactinomycin—melanoma	0.0052	0.00575	CcSEcCtD
Doxylamine—Erythema—Bleomycin—melanoma	0.00513	0.00567	CcSEcCtD
Doxylamine—Hallucination—Carmustine—melanoma	0.00512	0.00566	CcSEcCtD
Doxylamine—Flushing—Dactinomycin—melanoma	0.0051	0.00564	CcSEcCtD
Doxylamine—Hypersensitivity—Vemurafenib—melanoma	0.00509	0.00563	CcSEcCtD
Doxylamine—Hepatitis—Temozolomide—melanoma	0.00497	0.0055	CcSEcCtD
Doxylamine—Asthenia—Vemurafenib—melanoma	0.00496	0.00548	CcSEcCtD
Doxylamine—Hallucination—Temozolomide—melanoma	0.00495	0.00547	CcSEcCtD
Doxylamine—Urinary tract disorder—Temozolomide—melanoma	0.00491	0.00543	CcSEcCtD
Doxylamine—Pruritus—Vemurafenib—melanoma	0.00489	0.00541	CcSEcCtD
Doxylamine—Urethral disorder—Temozolomide—melanoma	0.00488	0.00539	CcSEcCtD
Doxylamine—Eye disorder—Carmustine—melanoma	0.00481	0.00532	CcSEcCtD
Doxylamine—Erythema—Dactinomycin—melanoma	0.00479	0.00529	CcSEcCtD
Doxylamine—Flushing—Carmustine—melanoma	0.00478	0.00528	CcSEcCtD
Doxylamine—Ill-defined disorder—Bleomycin—melanoma	0.00476	0.00526	CcSEcCtD
Doxylamine—Diarrhoea—Vemurafenib—melanoma	0.00473	0.00523	CcSEcCtD
Doxylamine—Erythema multiforme—Temozolomide—melanoma	0.0047	0.0052	CcSEcCtD
Doxylamine—Eye disorder—Temozolomide—melanoma	0.00465	0.00514	CcSEcCtD
Doxylamine—Malaise—Bleomycin—melanoma	0.00463	0.00512	CcSEcCtD
Doxylamine—Flushing—Temozolomide—melanoma	0.00462	0.0051	CcSEcCtD
Doxylamine—Cardiac disorder—Temozolomide—melanoma	0.00462	0.0051	CcSEcCtD
Doxylamine—Leukopenia—Bleomycin—melanoma	0.00459	0.00508	CcSEcCtD
Doxylamine—Dizziness—Vemurafenib—melanoma	0.00457	0.00505	CcSEcCtD
Doxylamine—Immune system disorder—Temozolomide—melanoma	0.00449	0.00497	CcSEcCtD
Doxylamine—Mediastinal disorder—Temozolomide—melanoma	0.00448	0.00495	CcSEcCtD
Doxylamine—Erythema—Carmustine—melanoma	0.00448	0.00495	CcSEcCtD
Doxylamine—Dehydration—Docetaxel—melanoma	0.00445	0.00491	CcSEcCtD
Doxylamine—Ill-defined disorder—Dactinomycin—melanoma	0.00444	0.00491	CcSEcCtD
Doxylamine—Vomiting—Vemurafenib—melanoma	0.0044	0.00486	CcSEcCtD
Doxylamine—Orthostatic hypotension—Docetaxel—melanoma	0.00437	0.00483	CcSEcCtD
Doxylamine—Rash—Vemurafenib—melanoma	0.00436	0.00482	CcSEcCtD
Doxylamine—Dermatitis—Vemurafenib—melanoma	0.00436	0.00481	CcSEcCtD
Doxylamine—Erythema—Temozolomide—melanoma	0.00433	0.00479	CcSEcCtD
Doxylamine—Breast disorder—Docetaxel—melanoma	0.00432	0.00478	CcSEcCtD
Doxylamine—Discomfort—Bleomycin—melanoma	0.00432	0.00477	CcSEcCtD
Doxylamine—Malaise—Dactinomycin—melanoma	0.00432	0.00477	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Docetaxel—melanoma	0.00431	0.00476	CcSEcCtD
Doxylamine—Cramp muscle—Docetaxel—melanoma	0.00431	0.00476	CcSEcCtD
Doxylamine—Leukopenia—Dactinomycin—melanoma	0.00429	0.00474	CcSEcCtD
Doxylamine—Nasopharyngitis—Docetaxel—melanoma	0.00428	0.00473	CcSEcCtD
Doxylamine—Confusional state—Bleomycin—melanoma	0.00422	0.00467	CcSEcCtD
Doxylamine—Tremor—Carmustine—melanoma	0.0042	0.00464	CcSEcCtD
Doxylamine—Anaphylactic shock—Bleomycin—melanoma	0.00419	0.00463	CcSEcCtD
Doxylamine—Agitation—Carmustine—melanoma	0.00412	0.00455	CcSEcCtD
Doxylamine—Nausea—Vemurafenib—melanoma	0.00411	0.00454	CcSEcCtD
Doxylamine—Thrombocytopenia—Bleomycin—melanoma	0.0041	0.00453	CcSEcCtD
Doxylamine—Bronchospasm—Docetaxel—melanoma	0.00406	0.00449	CcSEcCtD
Doxylamine—Tremor—Temozolomide—melanoma	0.00406	0.00448	CcSEcCtD
Doxylamine—Discomfort—Dactinomycin—melanoma	0.00403	0.00445	CcSEcCtD
Doxylamine—Ill-defined disorder—Temozolomide—melanoma	0.00402	0.00444	CcSEcCtD
Doxylamine—Leukopenia—Carmustine—melanoma	0.00401	0.00443	CcSEcCtD
Doxylamine—Anorexia—Bleomycin—melanoma	0.00399	0.00441	CcSEcCtD
Doxylamine—Agitation—Temozolomide—melanoma	0.00398	0.0044	CcSEcCtD
Doxylamine—Angioedema—Temozolomide—melanoma	0.00396	0.00437	CcSEcCtD
Doxylamine—Pancytopenia—Docetaxel—melanoma	0.00392	0.00434	CcSEcCtD
Doxylamine—Hypotension—Bleomycin—melanoma	0.00391	0.00433	CcSEcCtD
Doxylamine—Malaise—Temozolomide—melanoma	0.0039	0.00432	CcSEcCtD
Doxylamine—Vertigo—Temozolomide—melanoma	0.00389	0.0043	CcSEcCtD
Doxylamine—Convulsion—Carmustine—melanoma	0.00388	0.00429	CcSEcCtD
Doxylamine—Leukopenia—Temozolomide—melanoma	0.00388	0.00428	CcSEcCtD
Doxylamine—Palpitations—Temozolomide—melanoma	0.00383	0.00423	CcSEcCtD
Doxylamine—Thrombocytopenia—Dactinomycin—melanoma	0.00383	0.00423	CcSEcCtD
Doxylamine—Anxiety—Carmustine—melanoma	0.0038	0.0042	CcSEcCtD
Doxylamine—Convulsion—Temozolomide—melanoma	0.00375	0.00415	CcSEcCtD
Doxylamine—Dyspnoea—Bleomycin—melanoma	0.00373	0.00413	CcSEcCtD
Doxylamine—Anorexia—Dactinomycin—melanoma	0.00372	0.00412	CcSEcCtD
Doxylamine—Confusional state—Carmustine—melanoma	0.00369	0.00407	CcSEcCtD
Doxylamine—Anxiety—Temozolomide—melanoma	0.00367	0.00406	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00365	0.00404	CcSEcCtD
Doxylamine—Discomfort—Temozolomide—melanoma	0.00364	0.00403	CcSEcCtD
Doxylamine—Decreased appetite—Bleomycin—melanoma	0.00364	0.00402	CcSEcCtD
Doxylamine—Dry mouth—Temozolomide—melanoma	0.00361	0.00398	CcSEcCtD
Doxylamine—Thrombocytopenia—Carmustine—melanoma	0.00358	0.00396	CcSEcCtD
Doxylamine—Tachycardia—Carmustine—melanoma	0.00357	0.00394	CcSEcCtD
Doxylamine—Confusional state—Temozolomide—melanoma	0.00356	0.00394	CcSEcCtD
Doxylamine—Anaphylactic shock—Temozolomide—melanoma	0.00353	0.00391	CcSEcCtD
Doxylamine—Anorexia—Carmustine—melanoma	0.00349	0.00385	CcSEcCtD
Doxylamine—Nervous system disorder—Temozolomide—melanoma	0.00347	0.00383	CcSEcCtD
Doxylamine—Thrombocytopenia—Temozolomide—melanoma	0.00346	0.00382	CcSEcCtD
Doxylamine—Feeling abnormal—Bleomycin—melanoma	0.00345	0.00382	CcSEcCtD
Doxylamine—Agranulocytosis—Docetaxel—melanoma	0.00344	0.0038	CcSEcCtD
Doxylamine—Hypotension—Carmustine—melanoma	0.00342	0.00378	CcSEcCtD
Doxylamine—Hyperhidrosis—Temozolomide—melanoma	0.00342	0.00378	CcSEcCtD
Doxylamine—Decreased appetite—Dactinomycin—melanoma	0.0034	0.00375	CcSEcCtD
Doxylamine—Fatigue—Dactinomycin—melanoma	0.00337	0.00372	CcSEcCtD
Doxylamine—Anorexia—Temozolomide—melanoma	0.00337	0.00372	CcSEcCtD
Doxylamine—Urticaria—Bleomycin—melanoma	0.00333	0.00368	CcSEcCtD
Doxylamine—Hepatitis—Docetaxel—melanoma	0.00331	0.00366	CcSEcCtD
Doxylamine—Insomnia—Carmustine—melanoma	0.00331	0.00366	CcSEcCtD
Doxylamine—Urinary tract disorder—Docetaxel—melanoma	0.00327	0.00361	CcSEcCtD
Doxylamine—Dyspnoea—Carmustine—melanoma	0.00326	0.0036	CcSEcCtD
Doxylamine—Somnolence—Carmustine—melanoma	0.00325	0.00359	CcSEcCtD
Doxylamine—Urethral disorder—Docetaxel—melanoma	0.00324	0.00358	CcSEcCtD
Doxylamine—Feeling abnormal—Dactinomycin—melanoma	0.00322	0.00356	CcSEcCtD
Doxylamine—Insomnia—Temozolomide—melanoma	0.0032	0.00353	CcSEcCtD
Doxylamine—Decreased appetite—Carmustine—melanoma	0.00318	0.00351	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Carmustine—melanoma	0.00316	0.00349	CcSEcCtD
Doxylamine—Dyspnoea—Temozolomide—melanoma	0.00315	0.00348	CcSEcCtD
Doxylamine—Somnolence—Temozolomide—melanoma	0.00314	0.00347	CcSEcCtD
Doxylamine—Erythema multiforme—Docetaxel—melanoma	0.00313	0.00346	CcSEcCtD
Doxylamine—Constipation—Carmustine—melanoma	0.00313	0.00346	CcSEcCtD
Doxylamine—Eye disorder—Docetaxel—melanoma	0.00309	0.00342	CcSEcCtD
Doxylamine—Hypersensitivity—Bleomycin—melanoma	0.00309	0.00341	CcSEcCtD
Doxylamine—Decreased appetite—Temozolomide—melanoma	0.00307	0.00339	CcSEcCtD
Doxylamine—Flushing—Docetaxel—melanoma	0.00307	0.00339	CcSEcCtD
Doxylamine—Cardiac disorder—Docetaxel—melanoma	0.00307	0.00339	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Temozolomide—melanoma	0.00305	0.00337	CcSEcCtD
Doxylamine—Fatigue—Temozolomide—melanoma	0.00305	0.00337	CcSEcCtD
Doxylamine—Constipation—Temozolomide—melanoma	0.00302	0.00334	CcSEcCtD
Doxylamine—Feeling abnormal—Carmustine—melanoma	0.00301	0.00333	CcSEcCtD
Doxylamine—Asthenia—Bleomycin—melanoma	0.00301	0.00332	CcSEcCtD
Doxylamine—Immune system disorder—Docetaxel—melanoma	0.00299	0.0033	CcSEcCtD
Doxylamine—Mediastinal disorder—Docetaxel—melanoma	0.00298	0.00329	CcSEcCtD
Doxylamine—Pruritus—Bleomycin—melanoma	0.00296	0.00328	CcSEcCtD
Doxylamine—Feeling abnormal—Temozolomide—melanoma	0.00291	0.00322	CcSEcCtD
Doxylamine—Erythema—Docetaxel—melanoma	0.00288	0.00318	CcSEcCtD
Doxylamine—Hypersensitivity—Dactinomycin—melanoma	0.00288	0.00318	CcSEcCtD
Doxylamine—Urticaria—Temozolomide—melanoma	0.00281	0.0031	CcSEcCtD
Doxylamine—Asthenia—Dactinomycin—melanoma	0.0028	0.0031	CcSEcCtD
Doxylamine—Muscle spasms—Docetaxel—melanoma	0.00277	0.00306	CcSEcCtD
Doxylamine—Hypersensitivity—Carmustine—melanoma	0.00269	0.00298	CcSEcCtD
Doxylamine—Diarrhoea—Dactinomycin—melanoma	0.00267	0.00295	CcSEcCtD
Doxylamine—Vomiting—Bleomycin—melanoma	0.00266	0.00294	CcSEcCtD
Doxylamine—Rash—Bleomycin—melanoma	0.00264	0.00292	CcSEcCtD
Doxylamine—Dermatitis—Bleomycin—melanoma	0.00264	0.00292	CcSEcCtD
Doxylamine—Asthenia—Carmustine—melanoma	0.00262	0.0029	CcSEcCtD
Doxylamine—Hypersensitivity—Temozolomide—melanoma	0.0026	0.00288	CcSEcCtD
Doxylamine—Leukopenia—Docetaxel—melanoma	0.00258	0.00285	CcSEcCtD
Doxylamine—Palpitations—Docetaxel—melanoma	0.00254	0.00281	CcSEcCtD
Doxylamine—Asthenia—Temozolomide—melanoma	0.00254	0.0028	CcSEcCtD
Doxylamine—Diarrhoea—Carmustine—melanoma	0.0025	0.00277	CcSEcCtD
Doxylamine—Pruritus—Temozolomide—melanoma	0.0025	0.00276	CcSEcCtD
Doxylamine—Convulsion—Docetaxel—melanoma	0.00249	0.00276	CcSEcCtD
Doxylamine—Nausea—Bleomycin—melanoma	0.00249	0.00275	CcSEcCtD
Doxylamine—Vomiting—Dactinomycin—melanoma	0.00248	0.00275	CcSEcCtD
Doxylamine—Rash—Dactinomycin—melanoma	0.00246	0.00272	CcSEcCtD
Doxylamine—Dizziness—Carmustine—melanoma	0.00242	0.00267	CcSEcCtD
Doxylamine—Diarrhoea—Temozolomide—melanoma	0.00242	0.00267	CcSEcCtD
Doxylamine—Dry mouth—Docetaxel—melanoma	0.0024	0.00265	CcSEcCtD
Doxylamine—Confusional state—Docetaxel—melanoma	0.00237	0.00262	CcSEcCtD
Doxylamine—Anaphylactic shock—Docetaxel—melanoma	0.00235	0.0026	CcSEcCtD
Doxylamine—Dizziness—Temozolomide—melanoma	0.00234	0.00258	CcSEcCtD
Doxylamine—Vomiting—Carmustine—melanoma	0.00232	0.00257	CcSEcCtD
Doxylamine—Nausea—Dactinomycin—melanoma	0.00232	0.00256	CcSEcCtD
Doxylamine—Rash—Carmustine—melanoma	0.00231	0.00255	CcSEcCtD
Doxylamine—Nervous system disorder—Docetaxel—melanoma	0.0023	0.00255	CcSEcCtD
Doxylamine—Dermatitis—Carmustine—melanoma	0.0023	0.00255	CcSEcCtD
Doxylamine—Thrombocytopenia—Docetaxel—melanoma	0.0023	0.00254	CcSEcCtD
Doxylamine—Tachycardia—Docetaxel—melanoma	0.00229	0.00253	CcSEcCtD
Doxylamine—Vomiting—Temozolomide—melanoma	0.00225	0.00248	CcSEcCtD
Doxylamine—Anorexia—Docetaxel—melanoma	0.00224	0.00248	CcSEcCtD
Doxylamine—Rash—Temozolomide—melanoma	0.00223	0.00246	CcSEcCtD
Doxylamine—Dermatitis—Temozolomide—melanoma	0.00223	0.00246	CcSEcCtD
Doxylamine—Hypotension—Docetaxel—melanoma	0.0022	0.00243	CcSEcCtD
Doxylamine—Nausea—Carmustine—melanoma	0.00217	0.0024	CcSEcCtD
Doxylamine—Insomnia—Docetaxel—melanoma	0.00213	0.00235	CcSEcCtD
Doxylamine—Nausea—Temozolomide—melanoma	0.0021	0.00232	CcSEcCtD
Doxylamine—Dyspnoea—Docetaxel—melanoma	0.0021	0.00232	CcSEcCtD
Doxylamine—Somnolence—Docetaxel—melanoma	0.00209	0.00231	CcSEcCtD
Doxylamine—Decreased appetite—Docetaxel—melanoma	0.00204	0.00226	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Docetaxel—melanoma	0.00203	0.00224	CcSEcCtD
Doxylamine—Fatigue—Docetaxel—melanoma	0.00203	0.00224	CcSEcCtD
Doxylamine—Constipation—Docetaxel—melanoma	0.00201	0.00222	CcSEcCtD
Doxylamine—Feeling abnormal—Docetaxel—melanoma	0.00194	0.00214	CcSEcCtD
Doxylamine—Hypersensitivity—Docetaxel—melanoma	0.00173	0.00191	CcSEcCtD
Doxylamine—Asthenia—Docetaxel—melanoma	0.00169	0.00186	CcSEcCtD
Doxylamine—Pruritus—Docetaxel—melanoma	0.00166	0.00184	CcSEcCtD
Doxylamine—Diarrhoea—Docetaxel—melanoma	0.00161	0.00178	CcSEcCtD
Doxylamine—Dizziness—Docetaxel—melanoma	0.00155	0.00172	CcSEcCtD
Doxylamine—Vomiting—Docetaxel—melanoma	0.00149	0.00165	CcSEcCtD
Doxylamine—Rash—Docetaxel—melanoma	0.00148	0.00164	CcSEcCtD
Doxylamine—Dermatitis—Docetaxel—melanoma	0.00148	0.00164	CcSEcCtD
Doxylamine—Nausea—Docetaxel—melanoma	0.0014	0.00154	CcSEcCtD
Doxylamine—Orphenadrine—SCN10A—melanoma	0.00127	0.281	CrCbGaD
Doxylamine—Tamoxifen—CYP1B1—melanoma	0.000999	0.221	CrCbGaD
Doxylamine—Toremifene—ABCB1—melanoma	0.000718	0.159	CrCbGaD
Doxylamine—Tamoxifen—ABCB1—melanoma	0.000287	0.0635	CrCbGaD
Doxylamine—Doxepin—ABCB1—melanoma	0.000286	0.0633	CrCbGaD
Doxylamine—Methadone—ABCB1—melanoma	0.000284	0.0629	CrCbGaD
Doxylamine—Amitriptyline—ALB—melanoma	0.000232	0.0513	CrCbGaD
Doxylamine—Imipramine—ABCB1—melanoma	0.000222	0.0492	CrCbGaD
Doxylamine—Amitriptyline—ABCB1—melanoma	0.000221	0.0489	CrCbGaD
Doxylamine—HRH1—Signaling Pathways—CXCR1—melanoma	9.78e-05	0.00108	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SKI—melanoma	9.78e-05	0.00108	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCR1—melanoma	9.75e-05	0.00108	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SKI—melanoma	9.75e-05	0.00108	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MC1R—melanoma	9.64e-05	0.00106	CbGpPWpGaD
Doxylamine—HRH1—G alpha (q) signalling events—PIK3CA—melanoma	9.62e-05	0.00106	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MC1R—melanoma	9.6e-05	0.00106	CbGpPWpGaD
Doxylamine—CHRM1—G alpha (q) signalling events—PIK3CA—melanoma	9.59e-05	0.00106	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT3—melanoma	9.52e-05	0.00105	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT3—melanoma	9.49e-05	0.00105	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CXCR4—melanoma	9.47e-05	0.00105	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CXCR4—melanoma	9.44e-05	0.00104	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—GNAQ—melanoma	9.37e-05	0.00103	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	9.37e-05	0.00103	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—GNAQ—melanoma	9.34e-05	0.00103	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	9.34e-05	0.00103	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCR7—melanoma	9.24e-05	0.00102	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GRM1—melanoma	9.24e-05	0.00102	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GRM1—melanoma	9.21e-05	0.00102	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCR7—melanoma	9.21e-05	0.00102	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SUFU—melanoma	9e-05	0.000993	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SUFU—melanoma	8.97e-05	0.00099	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—TP53—melanoma	8.76e-05	0.000966	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT3—melanoma	8.65e-05	0.000954	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT3—melanoma	8.62e-05	0.000951	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	8.61e-05	0.00095	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	8.58e-05	0.000947	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—RHOB—melanoma	8.4e-05	0.000927	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—BCL2L11—melanoma	8.4e-05	0.000927	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—BCL2L11—melanoma	8.38e-05	0.000924	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RHOB—melanoma	8.38e-05	0.000924	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HDAC6—melanoma	8.07e-05	0.000891	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HDAC6—melanoma	8.05e-05	0.000888	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—IL6—melanoma	8.02e-05	0.000885	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—EDN1—melanoma	8e-05	0.000883	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—EDN1—melanoma	7.97e-05	0.00088	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	7.96e-05	0.000879	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	7.94e-05	0.000876	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CSF2—melanoma	7.82e-05	0.000863	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CSF2—melanoma	7.79e-05	0.00086	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCR2—melanoma	7.65e-05	0.000845	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CXCL8—melanoma	7.65e-05	0.000844	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCR2—melanoma	7.63e-05	0.000842	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CXCL8—melanoma	7.63e-05	0.000841	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	7.62e-05	0.000841	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	7.6e-05	0.000838	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—RAC2—melanoma	7.53e-05	0.000831	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RAC2—melanoma	7.51e-05	0.000828	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PRKCA—melanoma	7.5e-05	0.000827	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PRKCA—melanoma	7.47e-05	0.000824	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—WNT5A—melanoma	7.41e-05	0.000818	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VEGFC—melanoma	7.41e-05	0.000818	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VEGFC—melanoma	7.39e-05	0.000815	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—WNT5A—melanoma	7.39e-05	0.000815	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—EDN1—melanoma	7.26e-05	0.000802	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—EDN1—melanoma	7.24e-05	0.000799	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CSF2—melanoma	7.1e-05	0.000783	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CSF2—melanoma	7.08e-05	0.000781	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—RAC1—melanoma	6.95e-05	0.000767	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—RAC1—melanoma	6.93e-05	0.000764	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PRKCA—melanoma	6.81e-05	0.000751	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PRKCA—melanoma	6.78e-05	0.000749	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAP2K2—melanoma	6.65e-05	0.000734	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAP2K2—melanoma	6.63e-05	0.000732	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—F2R—melanoma	6.51e-05	0.000718	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—F2R—melanoma	6.49e-05	0.000716	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—RAC1—melanoma	6.31e-05	0.000696	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EDNRB—melanoma	6.3e-05	0.000696	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—RAC1—melanoma	6.29e-05	0.000694	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EDNRB—melanoma	6.28e-05	0.000693	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTK2B—melanoma	6.12e-05	0.000675	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTK2B—melanoma	6.1e-05	0.000673	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GAB2—melanoma	5.95e-05	0.000657	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GNA11—melanoma	5.95e-05	0.000657	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GAB2—melanoma	5.93e-05	0.000655	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GNA11—melanoma	5.93e-05	0.000655	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FLT1—melanoma	5.93e-05	0.000654	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FLT1—melanoma	5.91e-05	0.000652	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CG—melanoma	5.87e-05	0.000648	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CG—melanoma	5.85e-05	0.000646	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FOXO4—melanoma	5.6e-05	0.000618	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HDAC2—melanoma	5.6e-05	0.000618	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCR4—melanoma	5.6e-05	0.000618	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HDAC2—melanoma	5.58e-05	0.000616	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCR4—melanoma	5.58e-05	0.000616	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FOXO4—melanoma	5.58e-05	0.000616	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GNAQ—melanoma	5.53e-05	0.000611	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GNAQ—melanoma	5.52e-05	0.000609	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CG—melanoma	5.33e-05	0.000588	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CG—melanoma	5.31e-05	0.000586	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SYK—melanoma	5.2e-05	0.000574	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SYK—melanoma	5.19e-05	0.000572	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CD—melanoma	5.16e-05	0.00057	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CD—melanoma	5.14e-05	0.000568	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT3—melanoma	5.11e-05	0.000564	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NGFR—melanoma	5.11e-05	0.000564	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ITGAV—melanoma	5.11e-05	0.000564	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ITGAV—melanoma	5.09e-05	0.000562	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT3—melanoma	5.09e-05	0.000562	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NGFR—melanoma	5.09e-05	0.000562	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SOCS1—melanoma	4.73e-05	0.000522	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAP2K1—melanoma	4.72e-05	0.000521	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—S100B—melanoma	4.72e-05	0.000521	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SOCS1—melanoma	4.71e-05	0.00052	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAP2K1—melanoma	4.7e-05	0.000519	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—S100B—melanoma	4.7e-05	0.000519	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CD—melanoma	4.69e-05	0.000517	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CD—melanoma	4.67e-05	0.000516	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ERBB4—melanoma	4.51e-05	0.000498	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CB—melanoma	4.5e-05	0.000496	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ERBB4—melanoma	4.5e-05	0.000496	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CB—melanoma	4.48e-05	0.000495	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN2B—melanoma	4.47e-05	0.000493	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN2B—melanoma	4.46e-05	0.000492	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CD86—melanoma	4.33e-05	0.000477	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CXCL8—melanoma	4.32e-05	0.000477	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CD86—melanoma	4.31e-05	0.000476	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CXCL8—melanoma	4.31e-05	0.000476	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EDN1—melanoma	4.29e-05	0.000474	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EDN1—melanoma	4.28e-05	0.000472	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGF1—melanoma	4.19e-05	0.000463	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CSF2—melanoma	4.19e-05	0.000463	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CSF2—melanoma	4.18e-05	0.000461	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGF1—melanoma	4.18e-05	0.000461	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—IL2—melanoma	4.13e-05	0.000456	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—IL2—melanoma	4.12e-05	0.000454	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—E2F1—melanoma	4.1e-05	0.000453	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—E2F1—melanoma	4.09e-05	0.000451	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CB—melanoma	4.09e-05	0.000451	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CB—melanoma	4.07e-05	0.000449	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDGFRA—melanoma	4.06e-05	0.000448	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDGFRA—melanoma	4.05e-05	0.000447	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ITGB3—melanoma	4.02e-05	0.000444	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCA—melanoma	4.02e-05	0.000444	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCA—melanoma	4.01e-05	0.000442	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ITGB3—melanoma	4.01e-05	0.000442	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SPP1—melanoma	3.94e-05	0.000435	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAP2K2—melanoma	3.93e-05	0.000434	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SPP1—melanoma	3.93e-05	0.000434	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CXCL8—melanoma	3.93e-05	0.000433	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAP2K2—melanoma	3.92e-05	0.000432	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CXCL8—melanoma	3.91e-05	0.000432	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL2—melanoma	3.75e-05	0.000414	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL2—melanoma	3.74e-05	0.000413	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TERT—melanoma	3.74e-05	0.000412	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—RAC1—melanoma	3.73e-05	0.000411	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TERT—melanoma	3.73e-05	0.000411	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RAC1—melanoma	3.72e-05	0.00041	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HIF1A—melanoma	3.58e-05	0.000394	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HIF1A—melanoma	3.56e-05	0.000393	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KDR—melanoma	3.42e-05	0.000377	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KDR—melanoma	3.41e-05	0.000376	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FN1—melanoma	3.29e-05	0.000363	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FN1—melanoma	3.28e-05	0.000362	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOTCH1—melanoma	3.22e-05	0.000355	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOTCH1—melanoma	3.21e-05	0.000354	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CD80—melanoma	3.16e-05	0.000348	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CG—melanoma	3.15e-05	0.000348	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APC—melanoma	3.15e-05	0.000348	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KIT—melanoma	3.15e-05	0.000348	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—NRAS—melanoma	3.15e-05	0.000348	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CD80—melanoma	3.15e-05	0.000347	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APC—melanoma	3.14e-05	0.000346	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CG—melanoma	3.14e-05	0.000346	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KIT—melanoma	3.14e-05	0.000346	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—NRAS—melanoma	3.14e-05	0.000346	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EGF—melanoma	3.11e-05	0.000344	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EGF—melanoma	3.1e-05	0.000342	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAPK3—melanoma	3.02e-05	0.000333	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAPK3—melanoma	3.01e-05	0.000332	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—BRAF—melanoma	2.96e-05	0.000327	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—BRAF—melanoma	2.95e-05	0.000326	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IGF1—melanoma	2.88e-05	0.000318	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IGF1—melanoma	2.87e-05	0.000317	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAPK1—melanoma	2.87e-05	0.000317	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—EGFR—melanoma	2.87e-05	0.000317	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAPK1—melanoma	2.86e-05	0.000316	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—EGFR—melanoma	2.86e-05	0.000316	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAP2K1—melanoma	2.79e-05	0.000308	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAP2K1—melanoma	2.78e-05	0.000307	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CD—melanoma	2.77e-05	0.000306	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CD—melanoma	2.76e-05	0.000305	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CA—melanoma	2.74e-05	0.000303	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	2.73e-05	0.000302	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—KRAS—melanoma	2.71e-05	0.000299	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—KRAS—melanoma	2.7e-05	0.000298	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGF2—melanoma	2.65e-05	0.000293	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGF2—melanoma	2.64e-05	0.000292	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CA—melanoma	2.49e-05	0.000275	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CA—melanoma	2.48e-05	0.000274	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MDM2—melanoma	2.48e-05	0.000274	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MDM2—melanoma	2.47e-05	0.000273	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ERBB2—melanoma	2.45e-05	0.00027	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ERBB2—melanoma	2.44e-05	0.000269	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CB—melanoma	2.41e-05	0.000266	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CB—melanoma	2.41e-05	0.000265	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCL8—melanoma	2.32e-05	0.000256	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCL8—melanoma	2.31e-05	0.000255	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—HRAS—melanoma	2.3e-05	0.000254	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—HRAS—melanoma	2.3e-05	0.000253	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN1B—melanoma	2.26e-05	0.00025	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN1B—melanoma	2.26e-05	0.000249	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT1—melanoma	2.24e-05	0.000247	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT1—melanoma	2.23e-05	0.000246	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CASP3—melanoma	2.22e-05	0.000245	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL2—melanoma	2.22e-05	0.000245	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CASP3—melanoma	2.21e-05	0.000244	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL2—melanoma	2.21e-05	0.000244	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL6—melanoma	2.21e-05	0.000243	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL6—melanoma	2.2e-05	0.000243	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCND1—melanoma	2.16e-05	0.000238	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCND1—melanoma	2.15e-05	0.000238	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CTNNB1—melanoma	2.14e-05	0.000236	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CTNNB1—melanoma	2.13e-05	0.000235	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MMP9—melanoma	2.1e-05	0.000231	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MMP9—melanoma	2.09e-05	0.000231	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN1A—melanoma	2.09e-05	0.000231	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTEN—melanoma	2.09e-05	0.00023	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN1A—melanoma	2.08e-05	0.00023	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTEN—melanoma	2.08e-05	0.000229	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NFKB1—melanoma	2.08e-05	0.000229	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NFKB1—melanoma	2.07e-05	0.000228	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT1—melanoma	2.03e-05	0.000224	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT1—melanoma	2.03e-05	0.000224	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VEGFA—melanoma	1.88e-05	0.000208	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VEGFA—melanoma	1.88e-05	0.000207	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT3—melanoma	1.87e-05	0.000206	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NRAS—melanoma	1.86e-05	0.000205	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT3—melanoma	1.86e-05	0.000205	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NRAS—melanoma	1.85e-05	0.000205	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK3—melanoma	1.78e-05	0.000197	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK3—melanoma	1.78e-05	0.000196	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MYC—melanoma	1.73e-05	0.000191	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MYC—melanoma	1.73e-05	0.000191	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK1—melanoma	1.7e-05	0.000187	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EGFR—melanoma	1.7e-05	0.000187	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK1—melanoma	1.69e-05	0.000186	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EGFR—melanoma	1.69e-05	0.000186	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KRAS—melanoma	1.6e-05	0.000177	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KRAS—melanoma	1.6e-05	0.000176	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CA—melanoma	1.47e-05	0.000162	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CA—melanoma	1.47e-05	0.000162	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TP53—melanoma	1.42e-05	0.000157	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TP53—melanoma	1.42e-05	0.000157	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HRAS—melanoma	1.36e-05	0.00015	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HRAS—melanoma	1.36e-05	0.00015	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL6—melanoma	1.3e-05	0.000144	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL6—melanoma	1.3e-05	0.000143	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT1—melanoma	1.2e-05	0.000133	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT1—melanoma	1.2e-05	0.000132	CbGpPWpGaD
